QCLAB · Project

GPU-Powered Software That Runs Drug Molecule Simulations Dramatically Faster

digitalPilotedTRL 7

Imagine you need to test whether a new drug molecule actually works — but instead of spending months in a lab, you run the test on a computer. The problem is these simulations are incredibly slow, even on powerful machines. QCLAB built software that hijacks the graphics cards normally used for video games and turns them into chemistry supercomputers. The result? Calculations that used to take days can now finish in hours, letting pharmaceutical companies test far more drug candidates before committing to expensive lab work.

By the numbers

EUR 985,425

EU contribution for product scale-up

Project deliverables completed

SME developing and commercializing the technology

The business problem

What needed solving

Pharmaceutical and chemical companies rely on quantum chemistry simulations to test molecules before committing to lab experiments — but current software is painfully slow, bottlenecked by the sheer computational demand of integral calculations. This forces R&D teams to either wait days for results or limit the number of candidates they can evaluate, slowing down the entire product development pipeline.

The solution

What was built

QCLAB built a GPU-optimized quantum chemical integrator module — software that accelerates the most computationally expensive part of molecular simulations by running them on graphics processors. The project completed 10 deliverables including functional testing that validated the software for pharmaceutical docking calculations.

Audience

Who needs this

Pharmaceutical companies with computational chemistry R&D teamsContract research organizations offering molecular modeling servicesSpecialty chemical manufacturers developing new compoundsAcademic spin-offs commercializing drug discovery platformsQuantum chemistry software vendors looking for GPU acceleration plugins

Business applications

Who can put this to work

Pharmaceuticals

enterprise

Target: Mid-to-large pharma companies with in-house computational chemistry teams

If you are a pharmaceutical company dealing with slow and expensive drug candidate screening — this project developed a GPU-optimized quantum chemistry module that dramatically accelerates molecular simulations. Instead of waiting days for a single calculation, your computational chemists can evaluate more candidates faster, helping you find the perfect molecule with the right properties before committing to costly lab trials. The software integrates as a licensed module into your existing quantum chemistry software stack.

Contract Research Organizations

mid-size

Target: CROs offering computational drug design services

If you are a contract research organization competing on turnaround time for molecular modeling projects — this project built a GPU-accelerated integrator that plugs into standard quantum chemistry platforms. Faster calculations mean you can take on more client projects and deliver results sooner. With 10 deliverables completed including functional testing for pharmaceutical docking calculations, the technology was validated for real drug discovery workflows.

Chemical Manufacturing

mid-size

Target: Specialty chemicals companies developing new materials or compounds

If you are a chemical manufacturer spending months testing new compound formulations through trial and error — this project created software that simulates molecular interactions on GPU hardware at unprecedented speed. You can screen candidate compounds computationally before committing to expensive synthesis and physical testing, reducing development cycles and material waste for new product launches.

Frequently asked

Quick answers

What does this software cost and how is it licensed?

QCLAB's product is available as a licensed module that integrates with existing quantum chemistry software platforms. The project received EUR 985,425 in EU funding to develop and bring the module to market. Specific pricing details are not available in the project data, but the licensing model suggests per-seat or per-organization commercial terms.

Can this handle the scale of calculations we run in an industrial R&D setting?

Yes — the entire point of this project was solving the computational bottleneck that prevents industrial-scale quantum chemistry. The GPU-optimized integrator handles key calculation types including SCF, DFT, (RI)-MP2, and CC methods more efficiently than existing software. The functional testing deliverable specifically validated pharmaceutical docking calculations used by researchers and companies.

Who owns the intellectual property and can we license it?

The IP belongs to Streamnovation Kft., the Hungarian SME that developed and coordinated the project. As the sole consortium partner and a private company, they control all licensing decisions. The product was designed from the start as a commercial licensed module.

How does this integrate with our existing computational chemistry tools?

The software was specifically designed as a module that plugs into general quantum chemical software packages. This means you don't replace your current toolchain — you add the GPU-accelerated integrator as a component that speeds up the most computationally demanding part of your existing workflows.

What is the current development status?

The project ran from May 2017 to September 2019 under the EU's SME Instrument Phase 2, which funds companies that already have a working product and need to scale commercially. The functional testing deliverable confirmed the software can calculate docking information used directly by pharmaceutical researchers. Based on available project data, the product was approaching commercial readiness at project end.

What specific performance improvement can we expect?

The project objective states that GPU-optimized quantum chemical calculations can help companies significantly reduce time to market. The technology targets the integral calculation bottleneck — one of the main speed limitations in quantum chemistry. Based on available project data, specific benchmark numbers are not published in the project description.

Consortium

Who built it

This is a solo-SME project — Streamnovation Kft. from Hungary is the only partner, making it a focused commercial venture rather than a multi-partner research collaboration. The company received EUR 985,425 through the competitive SME Instrument Phase 2, which the EU reserves for companies with strong market potential. The 100% industry composition and SME status mean all decisions — licensing, pricing, partnerships — sit with one commercial entity. For a potential business customer, this simplifies negotiations: you deal with one company that owns everything.

How to reach the team

Streamnovation Kft. (Hungary) — reachable via brianqc.com, their commercial product site

Order a report on this consortium

Next steps

Talk to the team behind this work.

Want an introduction to the QCLAB team to discuss licensing for your R&D operations? SciTransfer can arrange a direct meeting with Streamnovation's leadership.

Order a report on this topic More in Digital & ICT